THE GENERAL HOSPITAL CORPORATION;GENZYME CORPORATION
发明人:
申请号：
IL19779709
公开号：
IL197797A
申请日:
2009.03.25
申请国别(地区):
IL
年份:
2017
代理人:
摘要：
The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-² antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-² antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
